SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM. Langerhans-cell histiocytosis ‘insight into DC biology.’ Trends Immunol. 2003; 24: 190196.
  • 2
    Imashuku S, Ikushima S, Hibi S, Todo S. Langerhans cell histiocytosis and hemophagocytic syndrome in Japan; epidemiological studies. Int J Pediatr Hematol Oncol. 1994; 1: 241246.
  • 3
    Gadner H, Ladisch S. The treatment of Langerhans cell histiocytosis. In: WeitzmanS, EgelerRM, editors. Histiocytic Disorders of Children and Adults; Basic Science, Clinical Features and Therapy. Cambridge: Cambridge University Press; 2005: 229253.
  • 4
    Donadieu J, Egeler RM, Pritchard J. Langerhans cell histiocytosis: a clinical update. In: WeitzmanS, EgelerRM, editors. Histiocytic Disorders of Children and Adults; Basic Science, Clinical Features and Therapy. Cambridge: Cambridge University Press; 2005: 95129.
  • 5
    Lahey ME. Histiocytosis X—comparison of three treatment regimens. J Pediatr. 1975; 87: 179183.
  • 6
    Ceci A, de Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: results from the Italian CooperativeAIEOP-CNR-H.X '83 study. Med Pediatr Oncol. 1993; 21: 259264.
  • 7
    Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol. 1994; 23: 7280.
  • 8
    Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr. 2000; 212: 139144.
  • 9
    Gadner H, Grois N, Arico M, et al., Histiocyte Society. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001; 138: 728734.
  • 10
    Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004; 42: 438444.
  • 11
    Grois N, Prayer D, Prosch H, Lassmann H, CNS LCH Co-operative Group. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain. 2005; 128(Pt 4): 829838.
  • 12
    Egeler RM, Neglia JP, Arico M, et al. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin North Am. 1998; 12: 369378.
  • 13
    Lahey E. Histiocytosis X—an analysis of prognostic factors. J Pediatr. 1975; 87: 184189.
  • 14
    Imashuku S, Ishida S, Koike K, et al., Japan LCH Study Group. Cerebellar ataxia in pediatric patients with Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2004; 26: 735739.
  • 15
    Titgemeyer C, Grois N, Minkov M, Flucher-Wolfram B, Gatterer-Menz I, Gadner H. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 2001; 37: 108114.
  • 16
    Egeler RM, de Kraker J, Voute PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol. 1993; 21: 265270.
  • 17
    Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H, DAL-HX Study Group. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol. 2002; 39: 581585.
  • 18
    Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer. 2005; 41: 26822689.
  • 19
    Suminoe A, Matsuzaki A, Hattori H, Ishii S, Hara T. Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2001; 23: 633636.
  • 20
    Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2005; 36: 215225.